https://ir.tuhurabio.com/ https://ir.tuhurabio.com/news-events/press-releases https://ir.tuhurabio.com/news-events/events https://ir.tuhurabio.com/news-events/presentations https://ir.tuhurabio.com/news-events/email-alerts https://ir.tuhurabio.com/company-information https://ir.tuhurabio.com/company-information/executive-team https://ir.tuhurabio.com/company-information/contacts https://ir.tuhurabio.com/company-information/faq https://ir.tuhurabio.com/financial-information/financial-results https://ir.tuhurabio.com/financial-information/income-statement https://ir.tuhurabio.com/financial-information/balance-sheet https://ir.tuhurabio.com/financial-information/cash-flow https://ir.tuhurabio.com/stock-data/quote-chart https://ir.tuhurabio.com/stock-data/historical-data https://ir.tuhurabio.com/stock-data/analyst-coverage https://ir.tuhurabio.com/sec-filings/all-sec-filings https://ir.tuhurabio.com/sec-filings/annual-reports https://ir.tuhurabio.com/sec-filings/quarterly-reports https://ir.tuhurabio.com/sec-filings/section-16-filings https://ir.tuhurabio.com/corporate-governance https://ir.tuhurabio.com/corporate-governance/board-of-directors https://ir.tuhurabio.com/corporate-governance/board-committees https://ir.tuhurabio.com/corporate-governance/governance-documents https://ir.tuhurabio.com/news-events/press-releases/detail/41/tuhura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update 2026-04-01T07:45:02-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/40/craig-tendler-m-d-jnjs-former-global-head-of-oncology-clinical-development-to-lead-tuhura-biosciences-vista-program-in-aml-and-other-blood-related-cancers 2026-03-23T07:45:02-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/39/tuhura-biosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement 2026-02-27T07:30:04-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/38/tuhura-biosciences-announces-participation-in-upcoming-investor-conferences 2026-02-24T17:20:01-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/37/tuhura-files-investigational-new-drug-application-for-tbs-2025-in-the-treatment-of-blood-related-cancers 2026-02-17T07:45:01-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/36/tuhura-biosciences-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-12T07:45:02-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/35/tuhura-biosciences-received-fda-orphan-drug-designation-for-ifx-2-0-for-the-treatment-of-stage-iib-to-stage-iv-cutaneous-melanoma 2026-02-02T07:45:02-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/34/tuhura-biosciences-announces-its-release-of-kintaras-contingent-value-right-cvr-as-kintaras-rem-001-meets-primary-safety-endpoint-achieving-contractual-milestone 2025-12-15T07:50:03-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/33/tuhura-biosciences-provides-corporate-update-following-recent-financing 2025-12-11T07:30:03-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/32/tuhura-biosciences-inc-announces-15-6-million-registered-direct-offering 2025-12-09T09:50:03-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/31/tuhura-biosciences-presents-data-demonstrating-the-delta-opioid-receptor-dor-as-a-new-target-in-overcoming-acquired-resistance-to-immune-checkpoint-inhibitors-at-the-57th-ash-annual-meeting-and-exposition 2025-12-08T07:50:01-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/30/tuhura-biosciences-inc-reports-third-quarter-2025-financial-results-and-provides-a-corporate-update 2025-11-14T07:00:09-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/29/tuhura-biosciences-discovery-research-on-targeting-the-delta-opioid-receptor-dor-to-reprogram-myeloid-derived-suppressor-cells-mdscs-selected-for-oral-presentation-at-the-67th-ash-annual-meeting-and-exposition 2025-11-03T09:02:15-05:00 https://ir.tuhurabio.com/news-events/press-releases/detail/28/tuhura-biosciences-inc-to-present-at-the-27th-annual-h-c-wainwright-global-investment-conference 2025-08-20T08:00:13-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/27/tuhura-biosciences-inc-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update 2025-08-14T16:15:08-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/5/tuhura-biosciences-inc-announces-inclusion-in-the-russell-3000-and-russell-2000-indexes 2025-07-02T14:05:38-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/6/tuhura-biosciences-completes-acquisition-of-kineta 2025-07-02T14:05:39-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/7/tuhura-biosciences-initiates-its-phase-3-accelerated-approval-trial-of-ifx-2-0-as-an-adjunctive-therapy-to-keytruda-pembrolizumab-in-first-line-treatment-for-advanced-or-metastatic-merkel-cell-carcinoma 2025-07-02T14:05:39-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/8/tuhura-biosciences-inc-and-kineta-inc-stockholders-approve-proposed-merger-and-all-related-proposals 2025-07-02T14:05:39-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/9/fda-removes-partial-clinical-hold-on-tuhura-biosciences-phase-3-accelerated-approval-trial-for-ifx-2-0-in-advanced-or-metastatic-merkel-cell-carcinoma 2025-07-02T14:05:39-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/10/tuhura-biosciences-inc-enters-into-12-5-million-equity-financing-transaction-and-receives-additional-3-0-million-in-warrant-exercise-proceeds-to-advance-its-pipeline-of-novel-treatments-to-overcome-primary-resistance-to-cancer-immunotherapy 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/11/tuhura-biosciences-presents-ifx-hu2-0-trial-in-progress-poster-at-the-2025-american-society-of-clinical-oncology-annual-meeting 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/12/tuhura-biosciences-inc-reports-first-quarter-2025-financial-results-and-provides-a-corporate-update 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/13/tuhura-biosciences-inc-to-present-at-the-3rd-annual-h-c-wainwright-bioconnect-conference 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/14/tuhura-biosciences-inc-initiates-phase-1b2a-study-of-ifx-hu2-0-as-an-adjunctive-therapy-to-keytruda-pembrolizumab-in-first-line-treatment-for-metastatic-merkel-cell-carcinoma-of-unknown-primary-origin-mccup 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/15/tuhura-biosciences-and-kineta-present-updated-results-from-kinetas-phase-i-ii-study-of-kva12123-and-tuhuras-mechanism-of-ifx-hu2-0-responses-after-anti-pd-1-therapy-failure-in-advanced-melanoma-at-the-american-association-for-cancer-research-annual-meeting 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/16/tuhura-biosciences-inc-announces-abstracts-accepted-for-poster-presentation-at-the-2025-aacr-annual-meeting 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/17/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/18/tuhura-biosciences-inc-reports-financial-results-for-fiscal-year-2024-and-provides-corporate-update 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/19/tuhura-biosciences-inc-appoints-craig-l-tendler-m-d-former-vice-president-oncology-clinical-development-diagnostics-and-global-medical-affairs-johnson-johnson-innovative-medicine-research-development-to-its-board-of-directors 2025-07-02T14:05:40-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/20/tuhura-biosciences-inc-to-present-at-the-37th-annual-roth-conference 2025-07-02T14:05:41-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/21/tuhura-biosciences-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference 2025-07-02T14:05:41-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/22/tuhura-biosciences-inc-enters-into-definitive-merger-agreement-to-acquire-kineta-inc 2025-07-02T14:05:41-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/23/tuhura-biosciences-inc-nasdaq-hura-outlines-development-pathway-for-single-phase-3-accelerated-approval-registration-trial-in-first-line-treatment-of-advanced-or-metastatic-merkel-cell-carcinoma-and-provides-business-update 2025-07-02T14:05:41-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/24/tuhura-biosciences-nasdaq-hura-announces-webcast-replay-of-panel-presentation-at-the-2024-maxim-healthcare-virtual-summit-presented-by-maxim-group-llc 2025-07-02T14:05:41-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/25/tuhura-biosciences-nasdaq-hura-to-present-at-the-virtual-investor-new-to-the-street-event 2025-07-02T14:05:42-04:00 https://ir.tuhurabio.com/news-events/press-releases/detail/26/tuhura-biosciences-completes-merger-transaction-with-kintara-therapeutics 2025-07-02T14:05:42-04:00 https://ir.tuhurabio.com/news-events/events/detail/20260310-citizens-life-science-conference 2026-02-24T17:24:01-05:00 https://ir.tuhurabio.com/news-events/events/detail/20260226-oppenheimer-36th-annual-healthcare-life-sciences-conference 2026-02-12T07:50:11-05:00 https://ir.tuhurabio.com/news-events/events/detail/20251211-tuhura-biosciences-corporate-update-call 2025-12-11T07:45:56-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0001193125-26-135766/hura-20260401.htm 2026-04-01T08:00:38-04:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0001193125-26-134950/hura-20251231.htm 2026-03-31T17:17:10-04:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000897069-26-000369/form4.html 2026-02-17T16:23:32-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000897069-26-000367/form4.html 2026-02-17T16:22:38-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000902664-26-001107/primary_doc.html 2026-02-17T16:21:55-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000897069-26-000365/form4.html 2026-02-17T16:19:46-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000897069-26-000363/form4.html 2026-02-17T16:17:01-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000897069-26-000360/form4.html 2026-02-17T16:10:51-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0001193125-26-031742/hura-20260129.htm 2026-01-30T16:01:12-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000897069-26-000112/form4.html 2026-01-08T16:35:46-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000897069-26-000111/form4.html 2026-01-08T16:34:14-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000897069-25-001809/form4.html 2025-12-17T06:38:34-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0000897069-25-001807/form4.html 2025-12-17T06:37:29-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0001193125-25-314302/d79925d8k.htm 2025-12-10T16:32:01-05:00 https://ir.tuhurabio.com/sec-filings/all-sec-filings/content/0001193125-25-313799/d27148d424b5.htm 2025-12-10T12:02:18-05:00 https://ir.tuhurabio.com/news-events/presentations/detail/9449/corporate-presentation 2026-04-03T14:50:11-04:00 https://ir.tuhurabio.com/disclaimer https://ir.tuhurabio.com/sitemap